Actively Recruiting
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
Led by University of Mississippi Medical Center · Updated on 2026-05-01
60
Participants Needed
1
Research Sites
505 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
CONDITIONS
Official Title
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women with preterm preeclampsia between 23 0/7 and 34 0/7 weeks gestation
- Able and willing to understand study procedures and provide informed consent
You will not qualify if you...
- Gestational age less than 23 weeks or greater than 33 weeks
- Maternal conditions requiring emergency delivery (placental abruption, DIC, pulmonary edema)
- Fetal conditions requiring emergency delivery (fetal bradycardia, recurrent late heart rate decelerations, minimal or absent variability)
- Preterm premature rupture of membranes beyond 34 weeks gestation
- Platelet count under 100,000/microliter with HELLP syndrome
- Persistently abnormal liver enzyme levels (twice above normal)
- Severe fetal growth restriction (fetal weight less than 5th percentile)
- Severe low amniotic fluid (AFI less than 5 cm)
- Reversal of end diastolic flow in umbilical artery Doppler
- Recurrent severe hypertension despite treatment
- Eclampsia
- Pulmonary edema
- Placental abruption
- Nonreassuring fetal status during daily testing (biophysical profile less than 4/10 or recurrent decelerations)
- Intrauterine fetal death
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Winfred L. Wiser Hospital
Jackson, Mississippi, United States, 39216
Actively Recruiting
Research Team
B
Babbette LaMarca, PhD
CONTACT
L
Lorena M Amaral, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here